First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer
-
- Keunchil Park
- Division of Haematology-Oncology, Samsung Medical Centre, Sungkyunkwan University School of Medicine, Seoul, Korea
-
- Chong-Jen Yu
- Department of Internal Medicine, National Taiwan University Hospital, Taipei City, Taiwan
-
- Sang-We Kim
- Department of Oncology, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, South Korea
-
- Meng-Chih Lin
- Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City, Taiwan 5Chang Gung University College of Medicine, Kaohsiung City, Taiwan
-
- Virote Sriuranpong
- Division of Medical Oncology, Chulalongkorn University, Bangkok, Thailand
-
- Chun-Ming Tsai
- Department of Chest Medicine, Taipei Veteran General Hospital, Taipei, Taiwan8School of Medicine, National Yang-Ming University, Taipei, Taiwan
-
- Jong-Seok Lee
- Department of Haematology and Medical Oncology, Seoul National University Bundang Hospital, Bundang, Korea
-
- Jin-Hyoung Kang
- Seoul St Mary’s Hospital, Seoul, Korea
-
- K. C. Allen Chan
- Department of Chemical Pathology, Chinese University of Hong Kong, Hong Kong
-
- Pablo Perez-Moreno
- F. Hoffmann–La Roche Ltd, Basel, Switzerland
-
- Peter Button
- Roche Products Pty Ltd, Dee Why, Australia
-
- Myung-Ju Ahn
- Division of Haematology-Oncology, Samsung Medical Centre, Sungkyunkwan University School of Medicine, Seoul, Korea
-
- Tony Mok
- State Key Laboratory of South China, Hong Kong Cancer Institute, Chinese University of Hong Kong, Sha Tin, Hong Kong
書誌事項
- タイトル別名
-
- The ASPIRATION Study
収録刊行物
-
- JAMA Oncology
-
JAMA Oncology 2 (3), 305-, 2016-03-01
American Medical Association (AMA)
